HUTCHMED (China) Ltd
HCM13.550USD
+0.200+1.50%
收盘 12/19, 16:00（美东）报价延迟15分钟
11.82B总市值
25.06市盈率 TTM
关于 HUTCHMED (China) Ltd 公司
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
HUTCHMED (China) Ltd简介
公司代码HCM
公司名称HUTCHMED (China) Ltd
上市日期May 19, 2006
CEOCheng (Chig Fung)
员工数量1811
证券类型Depository Receipt
年结日May 19
公司地址48th Floor, Cheung Kong Center, 2 Queen's Road Central
城市
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Hong Kong
邮编- -
电话85221281188
网址https://www.hutch-med.com/
公司代码HCM
上市日期May 19, 2006
CEOCheng (Chig Fung)
HUTCHMED (China) Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2024
FY2023
FY2022
FY2021
FY2020
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
其他
97.71%
持股股东
持股股东
占比
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
其他
97.71%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
2.31%
Investment Advisor
0.76%
Research Firm
0.22%
Hedge Fund
0.13%
Individual Investor
0.12%
Bank and Trust
0.03%
Sovereign Wealth Fund
0.01%
其他
96.41%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
144
6.22M
3.56%
-5.80M
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
2023Q2
352
26.00M
15.01%
-20.74M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Schroder Investment Management (Singapore) Ltd.
1.77M
1.02%
-97.80K
-5.23%
Jun 30, 2025
Allianz Global Investors Asia Pacific Limited
878.74K
0.5%
-67.00K
-7.08%
Jun 30, 2025
Schroder Investment Management (Hong Kong) Ltd.
805.63K
0.46%
-166.36K
-17.12%
Jun 30, 2025
Jane Street Capital, L.L.C.
175.96K
0.1%
-46.28K
-20.82%
Jun 30, 2025
State Street Investment Management (US)
328.79K
0.19%
-8.07K
-2.40%
Jun 30, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Jun 30, 2025
Amundi Asset Management, SAS
157.43K
0.09%
--
--
Jun 30, 2025
M&G Investment Management Ltd.
259.62K
0.15%
+924.00
+0.36%
Jun 30, 2025
Su (Weiguo Ph.D.)
183.98K
0.11%
+183.98K
--
Mar 04, 2024
Renaissance Technologies LLC
129.00K
0.07%
-6.20K
-4.59%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Tema Oncology ETF
0.78%
National Security Emerging Markets Index ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Tema Oncology ETF
占比0.78%
National Security Emerging Markets Index ETF
占比0.35%
Invesco Nasdaq Biotechnology ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
占比0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
占比0%
ActivePassive International Equity ETF
占比0%
SPDR Portfolio Developed World ex-US ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
HUTCHMED (China) Ltd的前五大股东是谁？
HUTCHMED (China) Ltd 的前五大股东如下：
Schroder Investment Management (Singapore) Ltd.持有股份：1.77M，占总股份比例：1.02%。
Allianz Global Investors Asia Pacific Limited持有股份：878.74K，占总股份比例：0.50%。
Schroder Investment Management (Hong Kong) Ltd.持有股份：805.63K，占总股份比例：0.46%。
Jane Street Capital, L.L.C.持有股份：175.96K，占总股份比例：0.10%。
State Street Investment Management (US)持有股份：328.79K，占总股份比例：0.19%。
Schroder Investment Management (Singapore) Ltd.持有股份：1.77M，占总股份比例：1.02%。
Allianz Global Investors Asia Pacific Limited持有股份：878.74K，占总股份比例：0.50%。
Schroder Investment Management (Hong Kong) Ltd.持有股份：805.63K，占总股份比例：0.46%。
Jane Street Capital, L.L.C.持有股份：175.96K，占总股份比例：0.10%。
State Street Investment Management (US)持有股份：328.79K，占总股份比例：0.19%。
HUTCHMED (China) Ltd的前三大股东类型是什么？
HUTCHMED (China) Ltd 的前三大股东类型分别是：
Schroder Investment Management (Singapore) Ltd.
Allianz Global Investors Asia Pacific Limited
Schroder Investment Management (Hong Kong) Ltd.
Schroder Investment Management (Singapore) Ltd.
Allianz Global Investors Asia Pacific Limited
Schroder Investment Management (Hong Kong) Ltd.
有多少机构持有HUTCHMED (China) Ltd(HCM)的股份？
截至2025Q3，共有144家机构持有HUTCHMED (China) Ltd的股份，合计持有的股份价值约为6.22M，占公司总股份的3.56%。与2025Q2相比，机构持股有所增加，增幅为-0.43%。
哪个业务部门对HUTCHMED (China) Ltd的收入贡献最大？
在FY2024，--业务部门对HUTCHMED (China) Ltd的收入贡献最大，创收--，占总收入的--%。
